Combining SX-682 with standard treatments for relapsed or refractory multiple myeloma

Phase 1 Trial of SX-682, a CXCR 1/2 Inhibitor, in Combination With Standard of Care Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

This study is testing if adding a new drug called SX-682 to standard treatments can help people with relapsed or refractory multiple myeloma feel better and fight their cancer more effectively.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Roswell Park Cancer Institute (Academic / other)
• Drugs / interventions: daratumumab, dratumumab
• Locations: 1 site (Buffalo, New York)
• Trial ID: NCT06622005 on ClinicalTrials.gov

What this trial studies

This phase I trial evaluates the safety and side effects of SX-682 when used alongside standard treatments such as carfilzomib, daratumumab-hyaluronidase, and dexamethasone in patients with relapsed or refractory multiple myeloma. SX-682 is designed to enhance the immune system's ability to target and destroy tumor cells by blocking specific sites that suppress immune function. The study aims to determine how well this combination works and to assess any potential side effects in participants. Patients will be monitored for measurable disease and must have received at least one prior line of therapy.

Who should consider this trial

Good fit: Ideal candidates include individuals with confirmed relapsed or refractory multiple myeloma who have measurable disease and have undergone at least one prior line of therapy.

Not a fit: Patients who do not have relapsed or refractory multiple myeloma or those who have not received prior treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment combination could improve outcomes for patients with difficult-to-treat multiple myeloma.

How similar studies have performed: Other studies have explored similar combinations in treating multiple myeloma, showing promising results, but this specific combination is novel.

Eligibility criteria

Inclusion Criteria:

* Confirmed relapsed/ refractory multiple myeloma
* Measurable disease including at least one of the following criteria:

  * Serum M-protein ≥ 0.5 g/dL
  * Urine M-protein ≥ 200 mg/24h
  * Serum free light chain assay: involved free light chain (FLC) level greater or equal to 100 mg/L provided serum free light chain ratio is abnormal
  * Bone marrow plasma cells ≥ 10% total bone marrow cells
* ≥ 1 prior line of therapy
* Planned treatment with a carfilzomib/daratumumab/dexamethasone regimen
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Absolute neutrophil count: ≥ 3 x 10\^9/L
* Platelets: ≥ 75 x 10\^9/L
* Hemoglobin: ≥ 7 g/dL
* Total bilirubin: ≤ 1.5 x upper limit of normal (ULN): ≤ 3.0 x ULN for Gilbert's syndrome
* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\]) / alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \[SGPT\]): ≤ 3 x ULN
* Renal Function: Estimated creatinine clearance ≥ 45 mL/min (Cockroft-Gault)
* Left ventricular ejection fraction of at least 50%
* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for 6 months following the last dose of the investigational drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
* Participant must understand the investigational nature of this study and sign an Independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

* Patients with non-secretory myeloma, systemic light chain amyloidosis or, plasmacytoma
* Intolerance to SX-682 or any other of the treatment components
* Refractory to prior carfilzomib (i.e. relapse or progression on or within 60 days after completion of treatment)
* Refractory to prior daratumumab (i.e. relapse or progression on or within 60 days after completion of treatment)
* Concomitant medication(s) known to be (a) a strong inhibitor or inducer of CYP3A4, or (b) QT prolonging as defined in the drug's approved label, with the exception of drugs that are considered absolutely essential for the care of the subject or if the investigator believes that beginning therapy with such medication is vital to an individual subject's care while on study, and in either case, there is no alternative medication
* Electrocardiogram (ECG) demonstrating a corrected QT (QTc) interval \> 470 msec or patients with congenital long QT syndrome
* Coronary artery bypass, angioplasty, vascular stent, myocardial infarction, angina or congestive heart failure in the last 6 months
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, class III or IV heart failure (New York Heart Association functional classification system) or psychiatric illness/social situations that would limit compliance with study requirements
* History of hepatitis B, C or HIV
* Known active bacillus tuberculosis infection
* Pregnant or nursing female participants
* Unwilling or unable to follow protocol requirements
* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug

Where this trial is running

Buffalo, New York

• Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States (Recruiting)

Study contacts

• Principal investigator: Jens Hillengass, MD — Roswell Park
• Study coordinator: Ask Rpci

Conditions Recurrent Multiple Myeloma; Refractory Multiple Myeloma